UK-432,097

UK-432,097
Kekulé skeletal formula of UK-432,097
Names
IUPAC name

6-(2,2-diphenylethylamino)-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-N-(2-(3-(1-(pyridin-2-yl)piperidin-4-yl)ureido)ethyl)-9H-purine-2-carboxamide
Identifiers
3D model (JSmol)
Abbreviations UK-432,097
ChemSpider
Properties
C40H47N11O6
Molar mass 777.887 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references

UK-432,097 is a drug developed by Pfizer for the treatment of chronic obstructive pulmonary disease, which acts as a potent and selective agonist of the adenosine A2A receptor.[1] It was discontinued from clinical trials following poor efficacy results,[2] but its high selectivity has made it useful for detailed mapping of the internal structure of the A2A receptor.[3]

References[edit]

  1. ^ Russo, Cristina; Arcidiacono, Giuseppe; Polosa, Riccardo (2006). “Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthma”. Fundamental and Clinical Pharmacology. 20 (1): 9–19. doi:10.1111/j.1472-8206.2005.00388.x. PMID 16448391.
  2. ^ Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease. ClinicalTrials.gov
  3. ^ Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, Stevens RC (March 2011). “Structure of an Agonist-Bound Human A2A Adenosine Receptor”. Science. 332 (6027): 322–7. doi:10.1126/science.1202793. PMC 3086811. PMID 21393508.